- Organizations: Sandoz
Legal
Regeneron settles with Sandoz over Eylea biosimilar patent infringement lawsuit
Agreement enables FDA-approved Enzeevu (aflibercept-abzv) to launch in Q4 2026, or potentially earlier.
Products
FDA approves Sandoz's EYLEA biosimilar for wet AMD
Approval of Enzeevu (aflibercept-abzv) is expected to be key in growing the company’s U.S. biosimilar-based ophthalmic portfolio.
Business
Sandoz completes acquisition of Coherus's ranibizumab biosimilar
Company looks to continue expanding its ophthalmology portfolio.
Business
Coherus is selling off its ophthalmology franchise to Sandoz
The $170 million deal includes the CIMERLI ophthalmology franchise, an interchangeable biosimilar of LUCENTIS.
Pipeline